Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma

Procarbazine, lomustine and vincristine (PCV) chemotherapy is considered a salvage option for adult glioma; however, its significant toxicities frequently lead to dose reduction or discontinuation in patients with recurrent glioma. The current study evaluated the safety and efficacy of modified proc...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2022-04, Vol.23 (4), Article 114
Main Authors: Ahn, Stephen, Kim, Young, Shin, Ja, Park, Jae-Sung, Yoo, Changyoung, Lee, Youn, Hong, Yong-Kil, Jeun, Sin-Soo, Yang, Seung
Format: Article
Language:English
Subjects:
Brain cancer
Chemotherapy
Clinical outcomes
Drug dosages
Glioma
Magnetic resonance imaging
Mutation
Neurotoxicity
Oncology
Radiation therapy
Surgery
Survival analysis
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Procarbazine, lomustine and vincristine (PCV) chemotherapy is considered a salvage option for adult glioma; however, its significant toxicities frequently lead to dose reduction or discontinuation in patients with recurrent glioma. The current study evaluated the safety and efficacy of modified procarbazine and lomustine (PC) chemotherapy that omits vincristine and reduces the lomustine dose compared with those of conventional PCV chemotherapy. Using electronic medical records, all patients with adult recurrent glioma who received PC or PCV chemotherapy between 2009 and 2020 at Seoul St. Mary's Hospital or St. Vincent's Hospital were examined retrospectively. A total of 59 patients met the eligibility criteria. Among them, 15 patients received modified PC chemotherapy (PC group) and 44 patients received PCV chemotherapy (PCV group). The PC group presented a significantly lower hematology toxicity (anemia, 6.7 vs. 45.5%, P=0.02; thrombocytopenia 20.0 vs. 70.4%, P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2022.13234